BRCA2 and ovarian carcinoma: Notably, AZD compounds did not change the mRNA expression of BRCA1/BRCA2 in ovarian cancer cells; however, AZD8835 could downregulate BRCA1/BRCA2 mRNA in KRAS-mutated OVCAR-8 cell via ERK signaling.